Zhifu Liu

Zhifu Liu

Auto-generated profile, based on publicly available information

Zhifu Liu

Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center National Research Center for Genitourinary Oncology Beijing China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2024 in iScience
Verified
Journal Article
Open access
ZLZhifu Liu
Zhifu Liu
SLSenmao Li
Senmao Li
SCShengbin Chen
Shengbin Chen
JSJindong Sheng
Jindong Sheng
ZLZheng Li
Zheng Li
JJJie Jin
Jie Jin
Benign prostatic hyperplasia (BPH) occurs when there is an imbalance between the proliferation and death of prostate cells, which is regulated tightly by estrogen signaling. However, the role of G protein-coupled estrogen receptor (GPER) in prostate cell survival remains ambiguous. In this study, we observed that prostates with epithelial hyperplasia showed increased yes-associated protein 1 (YAP) expression and decreased levels of estrogen and GPER. Blocking YAP through genetic or drug interventions led to reduced proliferation and increased apoptosis in the prostate epithelial cells. Interestingly, GPER agonists produced similar effects. GPER activation enhanced the phosphorylation and degradation of YAP, which was crucial for suppressing cell proliferation and survival. The Gαs/cAMP/PKA/LATS pathway, downstream of GPER, transmitted signals that facilitated YAP inhibition. This study investigated the interaction between GPER and YAP in the prostate epithelial cells and its contribution to BPH development. It lays the groundwork for future research on developing BPH treatments.

27 July 2025 in Aging Cell
Verified
Journal Article
Open access
ZLZheng Li
Zheng Li
XWXiaofei Wang
Xiaofei Wang
ZLZhifu Liu
Zhifu Liu
SLSenmao Li
Senmao Li
ZZZhenan Zhang
Zhenan Zhang
WYWei Yu
Wei Yu
Benign prostatic hyperplasia (BPH) is an age‐related condition characterized by progressive prostate enlargement driven in part by the accumulation of senescent epithelial cells and their pro‐inflammatory secretome. Using human single‐cell RNA sequencing and laser capture microdissection, we identified C‐X‐C Motif Chemokine Ligand 13 (CXCL13) as a key chemokine secreted by senescent prostate epithelial cells. CXCL13 recruits CD4+ T cells via the C‐X‐C Chemokine Receptor Type 5 (CXCR5) receptor, facilitating immune recognition through human leukocyte antigen–DR isotype (HLA‐DR) and promoting senescent cell clearance. Functional assays revealed that CD4+ cytotoxic T lymphocytes (CTLs) mediate this clearance, while regulatory T cells (Tregs) suppress it, forming a functional dichotomy. Immunohistochemistry, transwell migration, and co‐culture assays confirmed this CXCL13–CXCR5–HLA‐DR axis. In a testosterone‐induced BPH mouse model, CXCL13 treatment enhanced CD4+ T cell infiltration and reduced epithelial senescence, while CD4+ T cell depletion reversed these effects. Single‐cell transcriptomics in mice further validated increased CXCL13 expression and CD4+ T cell engagement. These findings uncover a critical immune surveillance mechanism in BPH and suggest that targeting the CXCL13–CD4+ T cell axis may offer a novel therapeutic strategy for age‐related prostate enlargement.

19 July 2025 in Experimental Cell Research
Verified
Journal Article
Open access
ZLZhifu Liu
Zhifu Liu
YTYuxuan Tian
Yuxuan Tian
ZLZheng Li
Zheng Li
ZLZhen Li
Zhen Li
KYKehao Yang
Kehao Yang
SHShuai Hu
Shuai Hu
The role of immune cells, particularly neutrophils, in the prostate cancer (PCa) progression remains poorly understood. In this study, we investigated the impact of neutrophils on PCa progression using an in vitro co-culture migration assay. Our findings revealed that PCa cells recruited more neutrophils than normal prostate epithelial cells. Importantly, the recruitment of neutrophils to PCa cells led to increased PCa cell proliferation. Further mechanistic investigations revealed that co-culture of PCa cells with neutrophils led to increased secretion of the chemokine CXCL1. This, in turn, stimulated neutrophils to produce the cytokine IL-8. The enhanced CXCL1/IL-8 signaling axis subsequently amplified androgen receptor (AR) signaling in PCa cells, thereby promoting their proliferation. Disruption of this pathway via IL-8 neutralizing antibodies or AR knockdown reversed the neutrophil-induced PCa cell proliferation. These findings were validated in a mouse model and further supported by clinical sample analysis. Collectively, our study highlights the therapeutic potential of targeting the newly identified signaling cascade involving infiltrating neutrophils within the PCa microenvironment. Understanding and modulating this pathway may offer novel strategies to suppress PCa progression.